Literature DB >> 7829604

The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.

J U Weaver1, J P Monson, K Noonan, W G John, A Edwards, K A Evans, J Cunningham.   

Abstract

GH deficiency is associated with increased cardiovascular morbidity, which may be determined by alterations in vascular risk factors. We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11). All patients were subsequently treated with GH for a further 6 months. Total fat, percent body fat, and central fat were measured by dual energy x-ray absorptiometry. The hypopituitary patients had increased percent fat (P = 0.03) and central fat (P < 0.01) compared with body mass index-matched controls. Before GH treatment, fasting (total) and specific insulin positively correlated with body mass index (P = 0.02 and P < 0.001, respectively), waist/hip ratio (P = 0.05 and P = 0.01), and central fat (P = 0.03 and P = 0.003). Specific insulin and insulin sensitivity (IS), calculated by homeostatic model of assessment, were related to total fat (P < 0.001 and P = 0.02). GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002). This was paralleled by a rise in fasting (total) and specific insulin (P = 0.016 and P = 0.002). The degree of correlation among indices of IS, body composition, and fat distribution increased after GH treatment. Fasting plasma glucose rose significantly, but was within the reference range. During 12 months of GH therapy, a significant increase in serum lipoprotein-(a) was observed (P < 0.05). Although GH has beneficial effects on central adiposity and lipid fractions, it is also associated with a decrease in IS; these effects may vary between individuals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829604     DOI: 10.1210/jcem.80.1.7829604

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

Review 1.  Effects of GH replacement on metabolism and physical performance in GH deficient adults.

Authors:  S K Abdul Shakoor; S M Shalet
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.

Authors:  Miriam A Bredella; Eleanor Lin; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Martin Torriani; Bijoy J Thomas; David A Schoenfeld; Anne Breggia; Clifford J Rosen; Linda C Hemphill; Zida Wu; Nader Rifai; Andrea L Utz; Karen K Miller
Journal:  Eur J Endocrinol       Date:  2012-01-24       Impact factor: 6.664

4.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

5.  Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Authors:  E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

6.  Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement.

Authors:  Luciana Diniz Carneiro Spina; Débora Vieira Soares; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Flávia Lúcia Conceição; Mário Vaisman
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

7.  The potential for growth hormone in the management of heart failure.

Authors:  J P Monson; G M Besser
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 8.  Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials.

Authors:  Connie B Newman; John D Carmichael; David L Kleinberg
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

9.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

10.  Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults.

Authors:  D Valle; M N D Di Minno; V Palmieri; S Pezzullo; F Cirillo; C Di Somma; G Di Minno; G Lombardi
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.